Biomolecular engineering of antidehydroepiandrosterone antibodies: a new perspective in cancer diagnosis and treatment using single-chain antibody variable fragment.
Nanomedicine (Lond)
; 14(6): 689-705, 2019 Mar.
Article
en En
| MEDLINE
| ID: mdl-30691340
ABSTRACT
AIM:
To develop a monoclonal antibody against dehydroepiandrosterone (DHEA) and miniaturize it, generating a single-chain antibody variable fragment (scFv) against DHEA as an adrenocortical carcinoma (ACC) marker. MATERIAL &METHODS:
DHEA conjugated to keyhole limpet hemocyanin was used as an immunogen to obtain anti-DHEA hybridomas. Variable fragments were cloned from hybridoma 5B7 total RNA, and used to detect DHEA in normal adrenal tissue and ACC cells.RESULTS:
IgM monoclonal antibody was highly specific, and the recombinant scFv preserved parental antibody characteristics, allowing tissue localization of DHEA.CONCLUSION:
Undefined small lesions are challenges for clinicians and impact clinical adrenocortical tumor management. Generating an anti-DHEA scFv facilitates development of imaging tests for early diagnosis of pediatric ACC.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Biomarcadores de Tumor
/
Neoplasias de la Corteza Suprarrenal
/
Deshidroepiandrosterona
/
Carcinoma Corticosuprarrenal
/
Anticuerpos de Cadena Única
Tipo de estudio:
Diagnostic_studies
/
Screening_studies
Límite:
Animals
/
Humans
Idioma:
En
Año:
2019
Tipo del documento:
Article